Comparative Pharmacology
Head-to-head clinical analysis: MPI DTPA KIT CHELATE versus MPI INDIUM DTPA IN 111.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DTPA KIT CHELATE versus MPI INDIUM DTPA IN 111.
MPI DTPA KIT - CHELATE vs MPI INDIUM DTPA IN 111
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DTPA (diethylenetriaminepentaacetic acid) chelates paramagnetic metal ions (e.g., gadolinium) to form stable complexes that alter T1 relaxation times during MRI, enhancing contrast.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Adult: 3-4 mCi (111-148 MBq) intravenously as a single dose for renal imaging.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
None Documented
None Documented
The terminal elimination half-life is approximately 1.7 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to >20 hours in severe renal impairment.
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Renal excretion accounts for >95% of the administered dose via glomerular filtration; less than 2% is excreted in feces.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical